Terms: = Bone cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Prognosis
137 results:
1. Development of a novel six DNA damage response-related prognostic signature in osteosarcoma.
Li T; Tang Z; Li S; Lu M
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):110-115. PubMed ID: 38650147
[TBL] [Abstract] [Full Text] [Related]
2. Expression of egfr and p16 in Squamous Cell Carcinoma of External Auditory Canal.
Kajimoto Y; Shinomiya H; Uehara N; Teshima M; Fujita T; Kakigi A; Imamura Y; Kiyota N; Miyawaki D; Sasaki R; Kimura H; Nibu KI
Kobe J Med Sci; 2024 Jan; 69(4):E144-E150. PubMed ID: 38379276
[TBL] [Abstract] [Full Text] [Related]
3. Exploration in the Mechanism of Ginsenoside Rg5 for the Treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.
Liu MY; Jiang DX; Zhao X; Zhang L; Zhang Y; Liu ZD; Liu RZ; Li HJ; Rong XY; Gao YZ
Orthop Surg; 2024 Feb; 16(2):462-470. PubMed ID: 38086608
[TBL] [Abstract] [Full Text] [Related]
4. Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets.
Høland M; Berg KCG; Eilertsen IA; Bjerkehagen B; Kolberg M; Boye K; Lingjærde OC; Guren TK; Mandahl N; van den Berg E; Palmerini E; Smeland S; Picci P; Mertens F; Sveen A; Lothe RA
EBioMedicine; 2023 Nov; 97():104829. PubMed ID: 37837931
[TBL] [Abstract] [Full Text] [Related]
5. Osteosarcoma's genetic landscape painted by genes' mutations.
Urban W; Krzystańska D; Piekarz M; Nazar J; Jankowska A
Acta Biochim Pol; 2023 Sep; 70(3):671-678. PubMed ID: 37717265
[TBL] [Abstract] [Full Text] [Related]
6. E-cadherin expression in the tumor microenvironment of advanced epidermal growth factor receptor-mutant lung adenocarcinoma and the association with prognosis.
Chang YP; Huang GK; Chen YC; Huang KT; Chen YM; Lin CY; Huang CC; Lin MC; Wang CC
BMC Cancer; 2023 Jun; 23(1):569. PubMed ID: 37340370
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological Features and prognosis of Lung Adenocarcinoma Patients With K-RAS Gene Mutation.
Sun D; Liu Y; Li P; Yang P; Yu G
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):406-413. PubMed ID: 37338109
[TBL] [Abstract] [Full Text] [Related]
8. prognosis prediction of icotinib as targeted therapy for advanced egfr-positive non-small cell lung cancer patients.
Tan X; Wang S; Xia H; Chen H; Xu J; Meng D; Wang Z; Li Y; Yang L; Jin Y
Invest New Drugs; 2023 Jun; 41(3):463-472. PubMed ID: 37140694
[TBL] [Abstract] [Full Text] [Related]
9. Identification of bone Metastatic and Prognostic Alternative Splicing Signatures in Prostate Adenocarcinoma.
Zhu J; Zhang J; Hu P; Fan M; Song D; Yin H; Yan P; Xian S; Li Z; Guo J; Long C; Xu R; Huang R; Meng T; Zhang J; Huang Z
Biochem Genet; 2023 Dec; 61(6):2242-2259. PubMed ID: 37010714
[TBL] [Abstract] [Full Text] [Related]
10. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
[TBL] [Abstract] [Full Text] [Related]
11. egfr inhibitor-induced folliculitis decalvans: a case series and management guidelines.
Nowaczyk J; Fret K; Kaminska-Winciorek G; Rudnicka L; Czuwara J
Anticancer Drugs; 2023 Sep; 34(8):942-948. PubMed ID: 36708507
[TBL] [Abstract] [Full Text] [Related]
12. Histone Methyltransferase KMT2B Promotes Metastasis and Angiogenesis of Cervical cancer by Upregulating EGF Expression.
Zhao D; Yuan H; Fang Y; Gao J; Li H; Li M; Cong H; Zhang C; Liang Y; Li J; Yang H; Yao M; Du M; Tu H; Gan Y
Int J Biol Sci; 2023; 19(1):34-49. PubMed ID: 36594087
[TBL] [Abstract] [Full Text] [Related]
13. The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.
Karkeet RM; Zekri AN; Sayed-Ahmed MM; Sherif GM; Salem SE; Abdelbary A; Fouad MA; Saad SY
PLoS One; 2022; 17(12):e0278282. PubMed ID: 36480560
[TBL] [Abstract] [Full Text] [Related]
14. De Novo mutation in Epidermal growth factor receptor (egfr)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.
Ding Y; Dong H; Li Y; Liu L; Cai Y; Wang Y; Tian S; Dai C
Medicine (Baltimore); 2022 Jul; 101(29):e29332. PubMed ID: 35866776
[TBL] [Abstract] [Full Text] [Related]
15. Clinical implications of ctDNA for egfr-TKIs as first-line treatment in NSCLC.
Liang X; Zhang W; Li J; Zhu J; Shao J; Wang J; Wu H; Dai J; Li J; Xu J; Wang W; Guo R
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1211-1220. PubMed ID: 35380256
[TBL] [Abstract] [Full Text] [Related]
16. Outstanding prognostic value of novel ferroptosis-related genes in chemoresistance osteosarcoma patients.
Zhao J; Zhao Y; Ma X; Feng H; Jia L
Sci Rep; 2022 Mar; 12(1):5029. PubMed ID: 35322804
[TBL] [Abstract] [Full Text] [Related]
17. Carcinomatosis under control by osimertinib in
Provenzano L; Cuccarini V; Platania M; Canziani L; Spagnoletti A; Doniselli FM; Eoli M; Prelaj A; Anghileri E
Tumori; 2021 Dec; 107(6):NP136-NP140. PubMed ID: 34727807
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic Factors in Lung Adenocarcinoma with bone Metastasis Treated with egfr-TKIs.
Chiu TH; Lin CY; Hsieh MH; Lin SM; Fang YF
Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577890
[No Abstract] [Full Text] [Related]
19. A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired egfr-T790M mutation: a real-world study.
Tang X; Li Y; Qian WL; Yan WF; Pang T; Gong YL; Yang ZG
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2475-2486. PubMed ID: 34536138
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic Signature of Osteosarcoma Based on 14 Autophagy-Related Genes.
Qi W; Yan Q; Lv M; Song D; Wang X; Tian K
Pathol Oncol Res; 2021; 27():1609782. PubMed ID: 34335109
[No Abstract] [Full Text] [Related]
[Next]
